These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 30342534)

  • 1. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.
    Ito M; Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Saito M
    Med Oncol; 2019 Sep; 36(10):89. PubMed ID: 31520329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
    Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
    Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
    Yang L; Lv Z; Xia W; Zhang W; Xin Y; Yuan H; Chen Y; Hu X; Lv Y; Xu Q; Weng X; Ni C
    Clin Transl Oncol; 2018 Jul; 20(7):912-921. PubMed ID: 29243075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Tanaka S; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):401-410. PubMed ID: 29277801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
    Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
    Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics.
    Chen W; Allen SG; Reka AK; Qian W; Han S; Zhao J; Bao L; Keshamouni VG; Merajver SD; Fu J
    BMC Cancer; 2016 Aug; 16():614. PubMed ID: 27501846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY; Wu S; Ma X; Liu Y
    Breast Cancer Res Treat; 2024 Oct; 207(3):517-527. PubMed ID: 38990453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer.
    Hyun KA; Koo GB; Han H; Sohn J; Choi W; Kim SI; Jung HI; Kim YS
    Oncotarget; 2016 Apr; 7(17):24677-87. PubMed ID: 27013581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
    Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.